Xeris Biopharma Holdings Total Liabilities (Quarterly) Insights

Xeris Biopharma Holdings Inc (XERS)

2.25 +0.03 (+1.35%) USD | NASDAQ | May 31, 16:00

2.255 0.00 (0.00%) After-Hours: 20:00

Total Liabilities (Quarterly) Chart

Historical Total Liabilities (Quarterly) Data

View and export this data back to 2017. Upgrade now.

Date	Value
March 31, 2024	345.79M
December 31, 2023	329.38M
September 30, 2023	323.92M
June 30, 2023	315.14M
March 31, 2023	291.31M
December 31, 2022	299.34M
September 30, 2022	247.98M
June 30, 2022	244.67M
March 31, 2022	241.17M
December 31, 2021	209.13M
September 30, 2021	133.72M
June 30, 2021	131.61M
March 31, 2021	123.25M

Date	Value
December 31, 2020	125.39M
September 30, 2020	156.05M
June 30, 2020	141.43M
March 31, 2020	89.39M
December 31, 2019	94.55M
September 30, 2019	84.44M
June 30, 2019	59.10M
March 31, 2019	53.87M
December 31, 2018	44.62M
September 30, 2018	42.47M
June 30, 2018	28.92M
March 31, 2018	28.71M
December 31, 2017	102.83M

Total Liabilities Definition

Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.

Read full definition.

Total Liabilities (Quarterly) Range, Past 5 Years

59.10M

Minimum

Jun 2019

345.79M

Maximum

Mar 2024

199.34M

Average

182.59M

Median

Total Liabilities (Quarterly) Benchmarks

Regeneron Pharmaceuticals Inc	7.378B
Vanda Pharmaceuticals Inc	108.69M
Adial Pharmaceuticals Inc	0.5627M
Kodiak Sciences Inc	193.57M
INmune Bio Inc	17.81M

Total Liabilities (Quarterly) Related Metrics

Total Assets (Quarterly)	336.62M
Shareholders Equity (Quarterly)	-9.178M
Debt to Equity Ratio	-25.02
Current Ratio	2.371
Net Debt Paydown Yield	-2.60%